ANI Pharma Enters Material Definitive Agreement

TL;DR

**ANI Pharma just signed a big deal, could be a game-changer!**

AI Summary

ANI Pharmaceuticals, Inc. filed an 8-K on February 23, 2024, reporting an event that occurred on February 16, 2024. The filing indicates an "Entry into a Material Definitive Agreement" and includes "Financial Statements and Exhibits." This suggests a significant new contractual obligation or partnership for the company.

Why It Matters

This filing signals a potentially significant strategic move or financial commitment for ANI Pharmaceuticals, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement without disclosing details, creating uncertainty about its financial implications and strategic impact.

Key Players & Entities

• ANI PHARMACEUTICALS INC (company) — Registrant
• Delaware (company) — State of incorporation
• February 16, 2024 (date) — Date of earliest event reported
• February 23, 2024 (date) — Filing date
• 001-31812 (dollar_amount) — Commission File Number

FAQ

Key Financial Figures

• $19,200,000 — Property") at a total purchase price of $19,200,000 Canadian dollars, or approximately $14,
• $14,200,000 — ,000 Canadian dollars, or approximately $14,200,000 US Dollars based on the current exchang
• $710,000 — of the purchase price, or approximately $710,000 US Dollars based on the current exchang

Filing Documents

• ani-20240216.htm (8-K) — 30KB
• anip-20240223xexx101.htm (EX-10.1) — 159KB
• 0001023024-24-000015.txt ( ) — 340KB
• ani-20240216.xsd (EX-101.SCH) — 2KB
• ani-20240216_lab.xml (EX-101.LAB) — 23KB
• ani-20240216_pre.xml (EX-101.PRE) — 12KB
• ani-20240216_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement On February 16, 2024, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of ANI Pharmaceuticals, Inc. ("ANI") entered into an agreement (the "Agreement") with 1540700 Ontario Limited ("Buyer") for the purchase and sale of ANI's Oakville, Ontario former manufacturing facility (the "Property") at a total purchase price of $19,200,000 Canadian dollars, or approximately $14,200,000 US Dollars based on the current exchange rate, subject to certain market adjustments. Under the terms and conditions of the Agreement, Buyer paid a deposit within two business days of signing of the Agreement of 5% of the purchase price, or approximately $710,000 US Dollars based on the current exchange rate, and Buyer's obligations under the Agreement are subject to a five (5) business day due diligence period (the "Due Diligence Condition"). Upon waiver or satisfaction of the Due Diligence Condition, Buyer is required to pay an additional deposit of 5% of the purchase price, or approximately $710,000 US Dollars based on the current exchange rate, with the remaining balance of the purchase price (minus the deposited amounts) to be paid upon closing of the transaction. The closing of the transaction is subject to customary termination conditions, including the Buyer's right to terminate the Agreement if the Property is materially damaged prior to the closing. If the transaction does not close as a result of the Due Diligence Condition or as a result of ANI's default under the Agreement, the deposited amounts will be returned to the Buyer in full. ANI will retain the deposited amounts if the transaction does not close as a result of the Buyer's default under the Agreement. Closing is expected to occur by the end of March 2024. The purchase of the Property is being made on an "as is" basis and the Agreement provides for customary closing conditions and indemnification obligations, as well as limited representations and warrantie

01 Exhibits

Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 10.1 Agreement of Purchase and Sale between ANI Pharmaceuticals Can ada , Inc. and 1540700 Ontario Limited 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 23, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR